Payers Enter the AI-and-Access Era

This April 2026 essay examines the intersection of medical spending, member access, authorization and specialty-drug operations. My strategic concern is that each function can optimize its own budget while increasing cost or delay elsewhere in the pathway. A lower administrative expense, faster determination or narrower network does not by itself establish a better result for the complete service.

I would therefore start with the payer’s economic exposure and the operating constraint it can influence. A proposal to reduce processing expense needs a cost-to-serve analysis. A proposal to improve access needs evidence of appropriate care reached. A proposal to reduce medical spending needs a credible comparison and sufficient follow-up. Combining all three in one return figure conceals the different assumptions required to support them.

The unit of analysis should be a resolved case, not a model response. For authorization, that means carrying the request through evidence collection, determination, communication and any appeal. For navigation, it means an available service that the member can actually use. For payment review, it means a substantiated decision after correction and dispute. Faster processing at one stage can increase the exception queue at the next; the evaluation must follow the work across that boundary.

The contract then determines whether value can be captured. Time released in an administrative team becomes financial value only if staffing, purchased services or productive capacity actually changes. Earlier care may increase near-term spending while improving access. A lower plan expense may shift documentation work to providers. I would make those transfers explicit so a favorable internal return is not mistaken for a reduction in total system cost.

The investment committee should see a base case excluding unverified medical offsets, an implementation case that includes integration and retained review, and a downside case for weaker adoption or higher exception rates. Member access and provider burden should remain decision criteria even where their effects cannot be monetized reliably. That is how I would distinguish an administrative efficiency purchase from a care-improvement thesis and fund each on its own evidence.

Start with the payer's constraint, not the product feature. Is the buyer trying to reduce authorization burden, improve access, manage specialty spend, close care gaps, or create a more defensible provider experience? The answer changes the ICP, the sales motion, the proof standard, and the implementation plan.

Then build the proof path before scaling the pitch. If the first deployment cannot show where time, cost, quality, or throughput improved, the company is still selling narrative instead of operating evidence.